TY - JOUR
T1 - Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis
AU - Karunakaran, Denuja
AU - Geoffrion, Michele
AU - Wei, Lihui
AU - Gan, Wei
AU - Richards, Laura
AU - Shangari, Prakriti
AU - DeKemp, Ella M.
AU - Beanlands, Rachelle A.
AU - Perisic, Ljubica
AU - Maegdefessel, Lars
AU - Hedin, Ulf
AU - Sad, Subash
AU - Guo, Liang
AU - Kolodgie, Frank D.
AU - Virmani, Renu
AU - Ruddy, Terrence
AU - Rayner, Katey J.
N1 - Funding Information:
We acknowledge the technical assistance of X. Zhao and J. Petryk. Funding: This work was supported by funding to K.J.R. from the Canadian Institutes of Health Research (MOP130365 and MSH130157). D.K. was supported by an Endowed Cardiovascular Genetics Postdoctoral Fellowship from the University of Ottawa Heart Institute. The BiKE study received support from the Swedish Heart and Lung Foundation, the Swedish Research Council (K2009-65X-2233-01-3, K2013-65X-06816-30-4, and 349-2007-8703), Uppdrag: Besegra Stroke (P581/2011-123), the Strategic Cardiovascular Programs of Karolinska Institutet and Stockholm County Council, and the Stockholm County Council (ALF2011-0260 and ALF-2011-0279), was approved by the Ethical Committee of Northern Stockholm, and met all international standards. Samples were collected with informed consent. Author contributions: D.K., L.R., P.S., E.M.D., and R.A.B. performed the in vitro studies of cell death and gene and protein expression. D.K., M.G., and K.J.R. performed the atherosclerosis studies. L.W., W.G., and T.R. synthesized the radiolabeled Nec-1 and evaluated the uptake. L.P., L.M., and U.H. performed the human carotid artery analysis. L.G., F.D.K., and R.V. performed the classification and characterization of the human coronary arteries before immunohistochemistry. S.S. and T.R. provided insight into the design of the experiments and the interpretation of the results. K.J.R. and D.K. designed the experiments and wrote the manuscript with input from all authors. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.
Publisher Copyright:
© 2016 The Authors.
PY - 2016/7/22
Y1 - 2016/7/22
N2 - Atherosclerosis results from maladaptive inflammation driven primarily by macrophages, whose recruitment and proliferation drive plaque progression. In advanced plaques, macrophage death contributes centrally to the formation of plaque necrosis, which underlies the instability that promotes plaque rupture and myocardial infarction. Hence, targeting macrophage cell death pathways may offer promise for the stabilization of vulnerable plaques. Necroptosis is a recently discovered pathway of programmed cell necrosis regulated by RIP3 and MLKL kinases that, in contrast to apoptosis, induces a proinflammatory state. We show herein that necroptotic cell death is activated in human advanced atherosclerotic plaques and can be targeted in experimental atherosclerosis for both therapeutic and diagnostic interventions. In humans with unstable carotid atherosclerosis, expression of RIP3 and MLKL is increased, and MLKL phosphorylation, a key step in the commitment to necroptosis, is detected in advanced atheromas. Investigation of the molecular mechanisms underlying necroptosis showed that atherogenic forms of low-density lipoprotein increase RIP3 and MLKL transcription and phosphorylation—two critical steps in the execution of necroptosis. Using a radiotracer developed with the necroptosis inhibitor necrostatin-1 (Nec-1), we show that 123I-Nec-1 localizes specifically to atherosclerotic plaques in Apoe−/− mice, and its uptake is tightly correlated to lesion areas by ex vivo nuclear imaging. Furthermore, treatment of Apoe−/− mice with established atherosclerosis with Nec-1 reduced lesion size and markers of plaque instability, including necrotic core formation. Collectively, our findings offer molecular insight into the mechanisms of macrophage cell death that drive necrotic core formation in atherosclerosis and suggest that this pathway can be used as both a diagnostic and therapeutic tool for the treatment of unstable atherosclerosis.
AB - Atherosclerosis results from maladaptive inflammation driven primarily by macrophages, whose recruitment and proliferation drive plaque progression. In advanced plaques, macrophage death contributes centrally to the formation of plaque necrosis, which underlies the instability that promotes plaque rupture and myocardial infarction. Hence, targeting macrophage cell death pathways may offer promise for the stabilization of vulnerable plaques. Necroptosis is a recently discovered pathway of programmed cell necrosis regulated by RIP3 and MLKL kinases that, in contrast to apoptosis, induces a proinflammatory state. We show herein that necroptotic cell death is activated in human advanced atherosclerotic plaques and can be targeted in experimental atherosclerosis for both therapeutic and diagnostic interventions. In humans with unstable carotid atherosclerosis, expression of RIP3 and MLKL is increased, and MLKL phosphorylation, a key step in the commitment to necroptosis, is detected in advanced atheromas. Investigation of the molecular mechanisms underlying necroptosis showed that atherogenic forms of low-density lipoprotein increase RIP3 and MLKL transcription and phosphorylation—two critical steps in the execution of necroptosis. Using a radiotracer developed with the necroptosis inhibitor necrostatin-1 (Nec-1), we show that 123I-Nec-1 localizes specifically to atherosclerotic plaques in Apoe−/− mice, and its uptake is tightly correlated to lesion areas by ex vivo nuclear imaging. Furthermore, treatment of Apoe−/− mice with established atherosclerosis with Nec-1 reduced lesion size and markers of plaque instability, including necrotic core formation. Collectively, our findings offer molecular insight into the mechanisms of macrophage cell death that drive necrotic core formation in atherosclerosis and suggest that this pathway can be used as both a diagnostic and therapeutic tool for the treatment of unstable atherosclerosis.
UR - http://www.scopus.com/inward/record.url?scp=85006622606&partnerID=8YFLogxK
U2 - 10.1126/sciadv.1600224
DO - 10.1126/sciadv.1600224
M3 - Article
C2 - 27532042
AN - SCOPUS:85006622606
VL - 2
JO - Science Advances
JF - Science Advances
SN - 2375-2548
IS - 7
M1 - e1600224
ER -